Lombard Medical, Inc. (EVARF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lombard Medical, Inc. (EVARF) trades at $0.0001 with AI Score 47/100 (Grade C). Lombard Medical, Inc. specializes in developing and marketing endovascular stent-grafts for aortic aneurysm repair. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for EVARF: EVARF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EVARF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EVARF: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Lombard Medical, Inc. (EVARF) Healthcare & Pipeline Overview
Lombard Medical, Inc. focuses on endovascular stent-grafts, particularly Aorfix for complex aortic aneurysms. With a global presence and direct sales model, the company competes in the medical device industry, facing challenges in a market with established players and stringent regulatory requirements, reflected in its negative profit margin.
What Is the Investment Thesis for EVARF?
Lombard Medical, Inc. presents a focused investment opportunity within the medical device sector, specifically in the endovascular aneurysm repair market. The company's Aorfix stent-graft addresses a niche segment of AAAs with challenging anatomies, potentially offering a competitive advantage. However, the company's negative profit margin of -255.0% and small market capitalization raise concerns about its financial sustainability. Growth catalysts include expanding market penetration in existing geographies and potential regulatory approvals in new markets. Investors should carefully consider the company's financial position, competitive landscape, and regulatory hurdles before making investment decisions. The company's beta of 0.64 suggests lower volatility than the overall market.
Based on FMP financials and quantitative analysis
EVARF Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with potential for high growth but also significant risk.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Profit Margin of -255.0% signals significant operational challenges and potential financial instability.
- Gross Margin of 7.8% suggests limited pricing power and high cost of goods sold.
- Beta of 0.64 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.
Who Are EVARF's Competitors?
EVARF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NVNO enVVeno Medical Corporation | $10.39 | -0.86% | 31 | |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EVARF's Key Strengths?
Specialized Aorfix stent-graft for complex anatomies.
- Proprietary delivery systems for precise placement.
- Direct sales force and distributor network.
- Focus on state-owned and government-owned hospitals.
What Are EVARF's Weaknesses?
Negative profit margin and small market capitalization.
- Limited product portfolio compared to larger competitors.
- Reliance on a few key products.
- Dependence on regulatory approvals for market expansion.
What Could Drive EVARF Stock Higher?
Potential regulatory approvals in new geographic markets, expanding market access.
- Continued adoption of Aorfix stent-graft among vascular surgeons.
- Expansion of clinical education and training programs.
What Are the Key Risks for EVARF?
Increased competition from larger medical device companies.
- Delays in regulatory approvals.
- Negative profit margin and financial instability.
- Limited liquidity due to OTC listing.
- Technological obsolescence.
What Are the Growth Opportunities for EVARF?
- Expansion into Emerging Markets: Lombard Medical has the opportunity to expand its geographic footprint into emerging markets with growing healthcare infrastructure and increasing awareness of endovascular procedures. These markets often present less competition and unmet clinical needs, allowing Lombard Medical to gain market share. Successful entry into these markets requires navigating local regulatory requirements and establishing distribution networks. The global market for endovascular aneurysm repair is projected to grow, offering a substantial opportunity for Lombard Medical to capitalize on this trend.
- Product Line Expansion: Lombard Medical can expand its product line to address a broader range of aortic diseases and anatomies. This could involve developing new stent-grafts, delivery systems, or adjunctive therapies. Expanding the product portfolio would allow Lombard Medical to target a larger patient population and increase its revenue streams. This strategy requires significant investment in research and development, as well as clinical trials to demonstrate safety and efficacy.
- Strategic Partnerships and Acquisitions: Lombard Medical could pursue strategic partnerships or acquisitions to expand its product portfolio, geographic reach, or technological capabilities. Partnering with larger medical device companies could provide access to established distribution networks and marketing resources. Acquiring complementary technologies or companies could accelerate product development and market entry. Successful partnerships and acquisitions require careful due diligence and integration planning.
- Focus on Clinical Education and Training: Lombard Medical can invest in clinical education and training programs to increase awareness and adoption of its products among vascular surgeons and interventional radiologists. Providing hands-on training and educational resources can help physicians overcome the learning curve associated with new technologies and techniques. This strategy can lead to increased product utilization and improved clinical outcomes. Clinical education and training programs can be delivered through workshops, conferences, and online platforms.
- Development of Next-Generation Stent-Graft Technology: Lombard Medical can invest in research and development to develop next-generation stent-graft technology with improved performance, durability, and ease of use. This could involve incorporating new materials, designs, or delivery systems. Developing innovative technology can provide a competitive advantage and attract new customers. This strategy requires significant investment in research and development, as well as clinical trials to demonstrate the superiority of the new technology.
What Threats Does EVARF Face?
- Competition from larger, established medical device companies.
- Stringent regulatory requirements and potential delays in approvals.
- Technological obsolescence.
- Economic downturns and healthcare budget constraints.
What Are EVARF's Competitive Advantages?
- Proprietary Aorfix stent-graft designed for complex anatomies.
- Specialized delivery systems for precise stent-graft placement.
- Established relationships with state-owned and government-owned hospitals.
- Intellectual property protection for key technologies.
What Does EVARF Do?
Founded in 2000 and headquartered in Didcot, UK, Lombard Medical, Inc. is a medical technology company focused on designing, manufacturing, and marketing advanced endovascular stent-grafts for the repair of aortic aneurysms. The company's flagship product, Aorfix, is a unique endovascular stent-graft specifically engineered for the treatment of abdominal aortic aneurysms (AAAs) with significant angulation at the neck of the aneurysm, up to 90 degrees. This addresses a critical need in treating patients with challenging anatomies. In addition to Aorfix, Lombard Medical offers the Altura endovascular stent graft system, designed for standard AAA anatomies. The company also provides specialized delivery systems, including the Aorflex delivery system for precise Aorfix placement and the IntelliFlex LP delivery system to enhance control during deployment. Lombard Medical distributes its products through a direct sales force and distributors, primarily targeting state-owned or government-owned hospitals across the United States, the United Kingdom, Germany, Japan, and other international markets. The company operates in a competitive landscape, facing established medical device companies.
What Products and Services Does EVARF Offer?
- Develops endovascular stent-grafts for aortic aneurysm repair.
- Manufactures Aorfix stent-graft for complex abdominal aortic aneurysms.
- Markets Aorfix and Altura stent-graft systems globally.
- Provides Aorflex and IntelliFlex delivery systems for precise stent-graft placement.
- Sells products directly and through distributors.
- Targets state-owned and government-owned hospitals.
How Does EVARF Make Money?
- Develops and manufactures endovascular stent-grafts.
- Sells products directly through a sales force and distributors.
- Generates revenue from stent-graft sales for aortic aneurysm repair.
- Focuses on state-owned and government-owned hospitals as primary customers.
What Industry Does EVARF Operate In?
Lombard Medical operates within the global medical device industry, specifically targeting the endovascular aneurysm repair (EVAR) market. This market is driven by an aging population, increasing prevalence of aortic aneurysms, and technological advancements in minimally invasive procedures. The competitive landscape includes larger, established medical device companies with broader product portfolios. Lombard Medical differentiates itself with its Aorfix stent-graft, designed for complex anatomies. The industry is subject to stringent regulatory requirements and ongoing technological innovation.
Who Are EVARF's Key Customers?
- State-owned hospitals
- Government-owned hospitals
- Vascular surgeons
- Interventional radiologists
Company Profile
Lombard Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Didcot, GB. The company is led by CEO Kurt Lemvigh. EVARF has traded publicly since 2014.
How Lombard Medical, Inc. Is Valued
Relative to its peer group, EVARF's quantitative score of 47/100 is roughly in line with the peer average of 57/100.
Key Financial Metrics
Return on assets is -45.8%, showing how much profit it generates from its asset base. A current ratio of 3.33 indicates the company holds enough short-term assets to cover its near-term obligations.
Earnings Track Record
Lombard Medical, Inc. has beaten Wall Street's EPS estimate in 4 of its last 6 reported quarters — more hits than misses. Reported results have landed about 1.9% above estimates on average.
EVARF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized Aorfix stent-graft for complex anatomies.
- Proprietary delivery systems for precise placement.
- Direct sales force and distributor network.
- Focus on state-owned and government-owned hospitals.
Bear Case
- Negative profit margin and small market capitalization.
- Limited product portfolio compared to larger competitors.
- Reliance on a few key products.
- Dependence on regulatory approvals for market expansion.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
EVARF Latest News
No recent news available for EVARF.
EVARF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVARF.
Price Targets
Wall Street price target analysis for EVARF.
EVARF MoonshotScore
What does this score mean?
The MoonshotScore rates EVARF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Kurt Lemvigh
CEO
Kurt Lemvigh serves as the Chief Executive Officer of Lombard Medical, Inc. His background includes experience in the medical device industry, with a focus on commercialization and market development. Prior to joining Lombard Medical, he held leadership positions at various medical technology companies, where he was responsible for driving revenue growth and expanding market share. He has a proven track record of successfully launching new products and building high-performing teams. His expertise lies in strategic planning, sales and marketing, and business development within the healthcare sector.
Track Record: Since assuming the role of CEO at Lombard Medical, Kurt Lemvigh has focused on streamlining operations, expanding the company's geographic reach, and driving adoption of the Aorfix stent-graft. Key initiatives include strengthening the sales force, establishing new distribution partnerships, and investing in clinical education programs. Under his leadership, the company has faced challenges related to profitability and market competition. His focus remains on achieving sustainable growth and improving financial performance.
EVARF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lombard Medical may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes.
- Established history in the medical device industry.
- Proprietary technology and products.
- Global presence and distribution network.
- Experienced management team.
Common Questions About EVARF (Healthcare)
What does the AI Score mean for EVARF?
EVARF holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Lombard Medical, Inc. specializes in developing and marketing endovascular stent-grafts for aortic aneurysm repair. Their primary product, Aorfix, addresses challenging anatomies, while they also …
What does Lombard Medical, Inc. do?
Lombard Medical, Inc. is a medical technology company that develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms. Their main product, Aorfix, is designed for abdominal aortic aneurysms with angulation at the neck, addressing a challenging anatomical subset. They also offer the Altura system for standard anatomies.
What are the main risks for EVARF?
The main risks for Lombard Medical, Inc. include its negative profit margin, indicating financial instability and potential difficulty in sustaining operations. Competition from larger medical device companies with greater resources poses a significant threat. Delays in regulatory approvals for new products or market expansion could hinder growth. As an OTC-listed stock, EVARF faces liquidity risks and limited regulatory oversight.
What are the key factors to evaluate for EVARF?
Lombard Medical, Inc. (EVARF) holds an AI score of 47/100 (low). presents a focused investment opportunity within the medical device sector, specifically in the endovascular aneurysm repair market. Not financial advice.
How frequently does EVARF data refresh on this page?
EVARF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven EVARF's recent stock price performance?
Lombard Medical, Inc. (EVARF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized Aorfix stent-graft for complex anatomies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EVARF overvalued or undervalued right now?
Lombard Medical, Inc. (EVARF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research EVARF before investing?
Before investing in Lombard Medical, Inc. (EVARF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding EVARF to a portfolio?
Key strength of Lombard Medical, Inc. (EVARF): Specialized Aorfix stent-graft for complex anatomies. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.